Edoceo Devices - Viral and Bacterial Detection Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Edoceo Devices - Viral and Bacterial Detection's estimated annual revenue is currently $775k per year.(i)
  • Edoceo Devices - Viral and Bacterial Detection's estimated revenue per employee is $155,000

Employee Data

  • Edoceo Devices - Viral and Bacterial Detection has 5 Employees.(i)
  • Edoceo Devices - Viral and Bacterial Detection grew their employee count by -17% last year.

Edoceo Devices - Viral and Bacterial Detection's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.7M110%N/AN/A
#2
$2.8M1813%N/AN/A
#3
$70.2M453-1%N/AN/A
#4
$1.6M10-66%N/AN/A
#5
$3.7M24-8%N/AN/A
#6
$2.9M3728%N/AN/A
#7
$3.1M2025%N/AN/A
#8
$2.5M16-20%N/AN/A
#9
$9.1M590%N/AN/A
#10
$4.2M27-7%N/AN/A
Add Company

What Is Edoceo Devices - Viral and Bacterial Detection?

Edoceo Devices is an emerging med-tech & biotech American company with Exclusive and Groundbreaking Biosensor Technology that could Help in the fight against COVID-19 – as well as Future Viral and Bacterial Threats to our normal family way of life. The priority is finalizing the development and marketing of this technology to produce two on-site proprietary detection biosensors - with the goal of providing essential rapid early warning to the presence of harmful pathogens: • Edoceo B-DetectTM - A portable virulent bacterial Testing device • Edoceo V-DetectTM - A portable virus biosensing device Edoceo B-Detect and V-Detect have the potential to change the world of rapid, portable, affordable, and accurate testing for pathogens including virulent bacteria and the presence of a range of viruses. These innovative detection platforms are being developed for the aquaculture, veterinary, health care, food processing and home monitoring markets, amongst others – Edoceo detection devices are based on the work of their Chief Science Officer, the Multi-Award-Winning Dr. Kenneth Reardon, in collaboration with many years of study and research by the scientists at Colorado State University that is exclusively licensed to Edoceo. *Breaking News* As a potential bonus to investors, and having secured substantial access to supplies, Edoceo Devices are commencing commercialization of a rapid (< 17 minutes), simple, saliva-based antigen test for the Coronavirus – Edoceo A-Detect which is already CE marked for distribution in the European Union and we are also planning a US FDA Emergency Use Application for distribution and sales in the United States.

keywords:N/A

N/A

Total Funding

5

Number of Employees

$775k

Revenue (est)

-17%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.4M50%N/A
#2
$0.4M50%N/A
#3
$0.4M50%N/A
#4
$0.4M5N/AN/A
#5
$0.4M50%N/A